Targeted Inhibition of Rad51 Renders Non–small Cell Lung Cancer Cells More Sensitive to Proton Therapy

International Journal of Radiation Oncology Biology Physics - Netherlands
doi 10.1016/j.ijrobp.2017.06.2034
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

A Decade of Targeted Therapy for Non-Small Cell Lung Cancer

2017English

Targeted Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2005English

ERK Inhibition Represses Gefitinib Resistance in Non-Small Cell Lung Cancer Cells

Oncotarget
Oncology
2018English

ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time

Cancer Cell
Cancer ResearchOncologyCell Biology
2010English

(-)-Guaiol Regulates RAD51 Stability via Autophagy to Induce Cell Apoptosis in Non-Small Cell Lung Cancer

Oncotarget
Oncology
2016English

Inhibition of SREBP Increases Gefitinib Sensitivity in Non-Small Cell Lung Cancer Cells

Oncotarget
Oncology
2016English

Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non–Small Cell Lung Cancer

Cancer Research
Cancer ResearchOncology
2017English

Recent Advances in Targeted Small-Molecule Inhibitor Therapy for Non-Small-Cell Lung Cancer-An Update

Journal of Clinical Pharmacy and Therapeutics
Pharmacology
2020English

Recent Progress in Rare Oncogenic Drivers and Targeted Therapy for Non-Small Cell Lung Cancer

OncoTargets and Therapy
OncologyPharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy